Farxiga reduced the relative risk of MACE by 16% in certain patients

Trial sub-analyses support CV effects of Farxiga in T2D

Positive results from a pre-specified sub-analysis of the Phase III DECLARE-TIMI 58 trial showed that Farxiga (dapagliflozin) reduced the relative risk of major adverse...
Bristol-Myers Squibb-Pfizer Alliance announces results from Phase 4 AUGUSTUS trial.

AUGUSTUS trial demonstrates favourable safety results

The Bristol-Myers Squibb-Pfizer Alliance has announced results from the Phase 4 AUGUSTUS trial evaluating Eliquis ® (apixaban) versus vitamin K antagonists (VKAs) in patients...
Trial results of Brilinta for heart attack patients following thrombolysis shows it met safety endpoint in secondary analysis of Phase III TREAT trial

EC approves Praluent®to reduce risk in ASCVD patients

The European Commission (EC) has approved a new indication for Praluent® (alirocumab), to reduce cardiovascular (CV) risk in adults with established atherosclerotic CV disease...
Pf Awards 2019 logo

Pharma talent on show at Pf Awards 2019

The biggest names in the pharmaceutical industry came together at the Royal Lancaster London on the evening of 14 March. The largest pharmaceutical sales...
Early access to atezolizumab for breast cancer

Early access to atezolizumab (Tecentriq®▼) and nab-paclitaxel for breast cancer

Adult patients in the UK with PD-L1 positive, unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) will be able to have early access...
European Medicines Agency adopts positive opinion for MSD’s KEYTRUDA®.

EMA adopts positive opinion for MSD’s KEYTRUDA®

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of a new extended dosing...
Call for female healthcare scientists to apply for NHS England leadership scheme

Call for female healthcare scientists to apply for leadership scheme

Female healthcare scientists are invited to apply for NHS England’s prestigious leadership development scheme, aimed at mid-career healthcare scientists. The aim of the scheme...

GHO Capital acquires Sterling Pharma Solutions

European specialist investor in healthcare, GHO Capital, has acquired a majority stake in Sterling Pharma Solutions, a specialist in complex and difficult to manufacture...
AstraZeneca will present its next generation oncology pipeline at AACR meeting in the US.

AstraZeneca to present immuno-oncology pipeline progress at AACR

AstraZeneca will share pioneering research and development across its oncology portfolio and extensive next-generation pipeline at the American Association for Cancer Research (AACR) Annual...
focus on science and not geography

Molecular patterns key to predicting breast cancer progression

The genetic and molecular make-up of individual breast tumours holds clues to how a woman’s disease could progress, including the likelihood of it coming...

Latest articles

focus on science and not geography

Greater global collaboration: Time to focus on science and not geography

The Pistoia Alliance is urging industry stakeholders worldwide to focus on science and not geography, in a call for greater global collaboration. More than 250...
Accelerating the MedTech landscape

Accelerating the MedTech landscape

The Academic Health Science Networks (AHSN) in partnership with the Association of British HealthTech Industries (ABHI) has launched a report on accelerating the MedTech...
Tescaro present data from the GARNET study on dostarlimab in endometrial cancer. 

Tescaro present data on dostarlimab in endometrial cancer

Tescaro release positive results from the GARNET study on dostarlimab in endometrial cancer.  TESARO, an oncology-focused business acquired by GlaxoSmithKline plc, presents data from the...

Popular articles

Bristol-Myers Squibb-Pfizer Alliance announces results from Phase 4 AUGUSTUS trial.

AUGUSTUS trial demonstrates favourable safety results

The Bristol-Myers Squibb-Pfizer Alliance has announced results from the Phase 4 AUGUSTUS trial evaluating Eliquis ® (apixaban) versus vitamin K antagonists (VKAs) in patients...
Smart phone image: Digital partnerships in pharma

Digital partnerships in pharma and the NHS

Can pharma and the NHS equal the fast pace of change necessary to fully embrace technological innovation? Over the last few years, slowly but surely,...
Trial results of Brilinta for heart attack patients following thrombolysis shows it met safety endpoint in secondary analysis of Phase III TREAT trial

Analysis of trial results of Brilinta for heart attack patients following thrombolysis

Analysis of trial results of Brilinta for heart attack patients following thrombolysis shows it met safety endpoint in secondary analysis of Phase III TREAT trial. The secondary...
The future of genomics

The future of genomics and precision medicine

How is the use of genomics data enhancing our medical understanding and what does this mean for the future of precision medicine? Genomics is one of...
Lixiana for Atrial Fibrillation

Daiichi Sanko announce results of two studies in the Edoxaban Clinical Research Programme

Daiichi Sankyo Company, Limited announces results from ELIMINATE-AF, a prospective, randomised, open label, blinded endpoint evaluation (PROBE) design study assessing the safety and efficacy...